Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1

被引:0
作者
Markus Wagner
Vincent Roh
Michael Strehlen
Alexander Laemmle
Deborah Stroka
Bernhard Egger
Markus Trochsler
Kelly K. Hunt
Daniel Candinas
Stephan A. Vorburger
机构
[1] University Hospital Bern and University of Bern,Department of Visceral and Transplantation Surgery and Department of Clinical Research, Inselspital
[2] University of Texas,Department of Surgical Oncology
[3] M.D. Anderson Cancer Center,undefined
来源
Journal of Gastrointestinal Surgery | 2009年 / 13卷
关键词
mTOR inhibitor; Rapamycin; 5-FU; Oxaliplatin; TIMP-1; Colorectal cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1781 / 1790
页数:9
相关论文
共 255 条
[1]  
Jemal A(2003)Cancer statistics, 2003 CA Cancer J Clin 53 5-26
[2]  
Murray T(2003)Review article: colorectal cancer chemotherapy Aliment Pharmacol Ther 18 683-692
[3]  
Samuels A(2004)Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer Br J Cancer 91 1420-1424
[4]  
Ghafoor A(2005)Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56 47-60
[5]  
Ward E(2007)Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer Cancer Lett 251 105-113
[6]  
Thun MJ(2002)Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 128-135
[7]  
Gill S(2005)Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF Blood 105 4463-4469
[8]  
Thomas RR(2004)Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy Clin Cancer Res 10 1843-1852
[9]  
Goldberg RM(2002)Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 7291-7297
[10]  
Chan S(2002)Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res 62 6141-6145